FLT3 and acute myeloid leukemia: Acute myeloid leukemia (AML), the dominant acute leukemia in adults, has shown survival gains with FLT3/IDH inhibitors and Bcl-2 antagonists; however, resistance and relapse limit the 5-year survival to approximately 30% [3,4].